Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to support research on (a) the causes of and (b) treatments for acute myeloid leukaemia.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department invests £1.5 billion per year on health research, through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was over £121.8 million for 2022/23, and more is spent on cancer than any other disease group.

The Government, through the NIHR, is committed to improving research into cancers with the poorest survival rates, such as acute myeloid leukaemia, by funding high quality, timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers. The following table shows NIHR research spend on diagnosis, treatment, and both diagnosis and treatment of blood cancers, including leukaemia, since 2018:

In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council’s two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.

The NIHR continues to encourage and welcome applications for research into any aspect of human health, including acute myeloid leukaemia. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether (a) it remains his policy to double the number of cancer scanners in the NHS and (b) that includes doubling the number of positron emission tomography scanners.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

We are working towards our commitment of doubling cancer scanners to address the challenges in diagnostic waiting times. Our commitment is related to magnetic resonance imaging and computed tomography (CT) but of course we are also considering what increase in PET Computed Tomography (PET-CT) capacity is needed to accelerate cancer diagnosis and build a National Health Service fit for the future.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps is he taking to evaluate the lung cancer diagnostic programme, and if he will roll this programme out to provide greater access for people who present a risk of lung cancer.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

The Targeted Lung Health Check (TLHC) is aimed at people who are over 55 years old, but younger than 75 years old, and who have a history of smoking, which puts them at a higher risk of lung cancer. The TLHC will be converted into a national lung cancer screening programme, which will be rolled out nationally by 2030.

The programme is currently being monitored by NHS England who are reviewing data gathered from the programme and quality assuring it. This data includes information on how many checks have been performed, along with invitations sent, and demographic information. Standards for the programme are being developed, for when the programme is fully rolled out.

Found: Cancer diagnosis patients waiting too long…. 

Found: stage; national cancer registration data (NCRD) and rapid cancer registra tion dataset (RCRD) |18112.9 Cancer

Found: Cancer diagnosis patients waiting too long…. 

Found: DRAFT FOR CONSULTATION 126 Early and locally advanced breast cancer: diagnosis and management : evidence

Found: National Institute for Health and Care Excellence Early and locally advanced breast cancer: diagnosis

Found: National Institute for Health and Care Excellence Draft Early and locally advanced breast cancer

Found: Informing the scope NG101 Early and locally advanced breast cancer : diagnosis and management

Found: list – Breast cancer: lymphoedema (update) Membership of Early and locally advanced breast cancer

Found: Page 1 of 2 ‘Early and locally advanced breast cancer: diagnosis and management - Lymphoedema

Found: cancer (MA review of TA781) [ID6287] Publication to be confirmed Related NICE g uidelines: Lung cancer

Found: ▪ OS – OS is calculated from the CDF treatment start date, not the date of a patient’s cancer diagnosis

Found: list – Breast cancer: lymphoedema (update) Membership of Early and locally advanced breast cancer

Found: TextComment11Finding out you had cancerIf there is anything else you would like to tell us about the lead-up to your cancer

Found: Text Comment 11 If there is anything else you would like to tell us about the lead -up to your cancer

Found: quality care whilst in hospital can help cancer patients to feel that they are viewed as more than their cancer

Found: This project support s people in Falkirk who are at risk of suicide or self -harm as a result of a cancer

Found: Routinely publish cancer diagnosis through emergency presentation data via PHS. 37.

Found: Diagnosis Services: but these aren’t enough.

Found: diagnosis and treatment safely and based on their clinical urgency.

Found: see attached brief in regards to Scotland’s earlier cancer diagnosis vision that’s in development and

Found: As part of our new 10 -year cancer strategy, we are publishing a new earlier cancer diagnosis vision